Tidal Investments LLC Has $2.69 Million Stock Position in Insulet Co. (NASDAQ:PODD)

Tidal Investments LLC boosted its stake in shares of Insulet Co. (NASDAQ:PODD - Free Report) by 9.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,283 shares of the medical instruments supplier's stock after purchasing an additional 918 shares during the quarter. Tidal Investments LLC's holdings in Insulet were worth $2,685,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. SBI Securities Co. Ltd. acquired a new position in Insulet during the 4th quarter valued at $36,000. Itau Unibanco Holding S.A. acquired a new position in Insulet during the 4th quarter valued at $42,000. SRS Capital Advisors Inc. raised its stake in shares of Insulet by 43.1% in the 4th quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier's stock valued at $49,000 after buying an additional 56 shares in the last quarter. Assetmark Inc. raised its stake in shares of Insulet by 1,447.1% in the 4th quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier's stock valued at $69,000 after buying an additional 246 shares in the last quarter. Finally, Blue Trust Inc. raised its stake in shares of Insulet by 117.3% in the 4th quarter. Blue Trust Inc. now owns 276 shares of the medical instruments supplier's stock valued at $72,000 after buying an additional 149 shares in the last quarter.

Insider Buying and Selling

In related news, Director Wayne A.I. Frederick sold 1,825 shares of Insulet stock in a transaction that occurred on Tuesday, March 25th. The shares were sold at an average price of $275.00, for a total transaction of $501,875.00. Following the transaction, the director now owns 3,231 shares of the company's stock, valued at $888,525. This trade represents a 36.10% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP John W. Kapples sold 5,278 shares of Insulet stock in a transaction that occurred on Wednesday, May 14th. The stock was sold at an average price of $318.47, for a total transaction of $1,680,884.66. Following the transaction, the senior vice president now directly owns 23,180 shares in the company, valued at $7,382,134.60. The trade was a 18.55% decrease in their position. The disclosure for this sale can be found here. 0.39% of the stock is owned by insiders.

Analyst Ratings Changes

A number of brokerages have recently issued reports on PODD. Wells Fargo & Company set a $322.00 price objective on shares of Insulet in a research note on Monday, April 28th. Wall Street Zen cut shares of Insulet from a "buy" rating to a "hold" rating in a research note on Thursday, May 22nd. Sanford C. Bernstein restated an "outperform" rating on shares of Insulet in a research note on Friday, May 16th. Stifel Nicolaus increased their price objective on shares of Insulet from $245.00 to $293.00 and gave the company a "hold" rating in a research note on Friday, February 21st. Finally, Citigroup reaffirmed a "buy" rating and issued a $380.00 target price (up previously from $320.00) on shares of Insulet in a report on Thursday, May 22nd. Four investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $308.00.

Insulet Trading Up 2.0%

Insulet stock traded up $6.31 during trading hours on Tuesday, reaching $327.67. 94,529 shares of the company's stock traded hands, compared to its average volume of 786,931. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. Insulet Co. has a fifty-two week low of $171.61 and a fifty-two week high of $329.33. The firm has a market capitalization of $23.06 billion, a price-to-earnings ratio of 56.51, a PEG ratio of 3.62 and a beta of 1.26. The firm's 50 day moving average is $272.24 and its 200-day moving average is $270.26.

Insulet (NASDAQ:PODD - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.02 earnings per share for the quarter, topping the consensus estimate of $0.81 by $0.21. Insulet had a net margin of 20.19% and a return on equity of 24.46%. The business had revenue of $569.00 million for the quarter, compared to analyst estimates of $543.20 million. During the same quarter last year, the firm earned $0.73 EPS. Insulet's quarterly revenue was up 28.8% compared to the same quarter last year. On average, analysts predict that Insulet Co. will post 3.92 earnings per share for the current year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.